BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 40,000 shares of the firm's stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $74.40, for a total value of $2,976,000.00. Following the sale, the chief executive officer owned 775,686 shares of the company's stock, valued at approximately $57,711,038.40. This trade represents a 4.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Neil Kumar also recently made the following trade(s):
- On Thursday, November 20th, Neil Kumar sold 26,156 shares of BridgeBio Pharma stock. The stock was sold at an average price of $65.84, for a total value of $1,722,111.04.
- On Thursday, November 6th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $63.15, for a total value of $2,526,000.00.
- On Wednesday, October 8th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $54.78, for a total transaction of $2,191,200.00.
BridgeBio Pharma Trading Up 0.8%
Shares of NASDAQ:BBIO opened at $74.24 on Tuesday. The firm has a market cap of $14.31 billion, a PE ratio of -17.76 and a beta of 1.25. The company has a fifty day simple moving average of $62.45 and a 200 day simple moving average of $51.69. BridgeBio Pharma, Inc. has a 12-month low of $25.34 and a 12-month high of $75.10.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.07). The business had revenue of $120.70 million for the quarter, compared to analysts' expectations of $107.71 million. BridgeBio Pharma's revenue was up 4318.0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.86) EPS. As a group, equities research analysts forecast that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.
Analyst Ratings Changes
A number of equities analysts recently commented on the company. Truist Financial reiterated a "buy" rating and issued a $80.00 price target (up from $66.00) on shares of BridgeBio Pharma in a research note on Thursday, October 30th. HC Wainwright reaffirmed a "buy" rating and set a $90.00 target price on shares of BridgeBio Pharma in a report on Monday, November 3rd. UBS Group lifted their target price on BridgeBio Pharma from $72.00 to $82.00 and gave the stock a "buy" rating in a research report on Friday, September 12th. Cantor Fitzgerald upped their price target on BridgeBio Pharma from $100.00 to $110.00 and gave the company an "overweight" rating in a research report on Thursday, October 30th. Finally, TD Cowen raised their price objective on BridgeBio Pharma from $60.00 to $95.00 and gave the stock a "buy" rating in a research note on Thursday, October 30th. Twenty research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $74.37.
Read Our Latest Stock Analysis on BBIO
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Swiss Life Asset Management Ltd acquired a new stake in BridgeBio Pharma in the third quarter worth $346,000. CIBC Private Wealth Group LLC boosted its holdings in shares of BridgeBio Pharma by 384.0% during the third quarter. CIBC Private Wealth Group LLC now owns 7,759 shares of the company's stock valued at $403,000 after acquiring an additional 6,156 shares during the period. CIBC Bancorp USA Inc. bought a new position in shares of BridgeBio Pharma during the third quarter worth about $866,000. Danske Bank A S acquired a new stake in shares of BridgeBio Pharma in the 3rd quarter worth about $104,000. Finally, Castleark Management LLC increased its holdings in shares of BridgeBio Pharma by 58.9% in the 3rd quarter. Castleark Management LLC now owns 123,707 shares of the company's stock worth $6,425,000 after acquiring an additional 45,867 shares during the period. Institutional investors and hedge funds own 99.85% of the company's stock.
BridgeBio Pharma Company Profile
(
Get Free Report)
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
